title: Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
abstract: To better understand humoral immunity following ebolavirus infection, a serological study of the humoral immune response against the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed. An enzyme-linked immunosorbent assay specific for full-length recombinant viral proteins NP, VP30, VP40, and GP1-649 (GP lacking the transmembrane domain) of Sudan ebolavirus (Gulu) was used as well as a plaque reduction neutralization test. Serum samples from human survivors, which were collected up to 10 years following recovery, were screened and analyzed. Results demonstrate that samples obtained 10 years following infection contain virus-specific antibodies that can neutralize virus. Neutralization correlates well with immunoreactivity against the viral proteins NP, VP30, and GP1-649. Sera from individuals who died or those with no documented infection but immunoreactive to ebolavirus did not neutralize. This work provides insight into the duration, profile of immunoreactivity, and neutralization capacity of the humoral immune response in ebolavirus survivors.
authors.affiliation: Department of Virology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
authors.forename: Ariel
authors.initials: A
authors.lastname: Sobarzo
authors.forename: Allison
authors.initials: A
authors.lastname: Groseth
authors.forename: Olga
authors.initials: O
authors.lastname: Dolnik
authors.forename: Stephan
authors.initials: S
authors.lastname: Becker
authors.forename: Julius Julian
authors.initials: JJ
authors.lastname: Lutwama
authors.forename: Eddie
authors.initials: E
authors.lastname: Perelman
authors.forename: Victoria
authors.initials: V
authors.lastname: Yavelsky
authors.forename: Majidat
authors.initials: M
authors.lastname: Muhammad
authors.forename: Ana I
authors.initials: AI
authors.lastname: Kuehne
authors.forename: Robert S
authors.initials: RS
authors.lastname: Marks
authors.forename: John M
authors.initials: JM
authors.lastname: Dye
authors.forename: Leslie
authors.initials: L
authors.lastname: Lobel
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology*; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D000956:Antigens, Viral / Q000097:blood / Q000276:immunology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D029043:Ebolavirus / Q000276:immunology*; D057809:HEK293 Cells; D019142:Hemorrhagic Fever, Ebola / Q000097:blood / Q000276:immunology* / Q000821:virology; D006801:Humans; D056724:Immunity, Humoral / Q000276:immunology; D007070:Immunoglobulin A / Q000276:immunology; D009500:Neutralization Tests / Q000379:methods; D013397:Sudan; D017741:Survivors; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D007070:Immunoglobulin A; D014759:Viral Envelope Proteins
keywords: antibodies; ebolavirus; epitopes; immune response; sera screening; serological profiling